OMB Presses Agency Heads For 2013 Budget Reductions
This article was originally published in The Gray Sheet
White House Office of Management and Budget Director Jack Lew has asked federal agency heads to submit a fiscal 2013 budget request that is at least 5% lower than 2011 funding.
You may also be interested in...
Commissioner Margaret Hamburg’s reorganization at the top of FDA puts an expert in pediatric drug development and pharmacogenomics in a new post overseeing four of the seven agency centers, including the device unit.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.